Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $30.65 USD
Change Today -0.88 / -2.79%
Volume 38.7K
As of 8:10 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

paratek pharmaceuticals inc (PRTK) Snapshot

Open
$31.82
Previous Close
$31.53
Day High
$31.82
Day Low
$30.23
52 Week High
12/31/14 - $39.80
52 Week Low
10/24/14 - $11.30
Market Cap
441.9M
Average Volume 10 Days
31.0K
EPS TTM
$-12.31
Shares Outstanding
14.4M
EX-Date
10/31/14
P/E TM
--
Dividend
--
Dividend Yield
78.20%
Current Stock Chart for PARATEK PHARMACEUTICALS INC (PRTK)

paratek pharmaceuticals inc (PRTK) Related Bloomberg News

View More Bloomberg News

paratek pharmaceuticals inc (PRTK) Related Businessweek News

No Related Businessweek News Found

paratek pharmaceuticals inc (PRTK) Details

Paratek Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines to save lives and alleviate suffering. Its lead product candidate, omadacycline, is a tetracycline-derived, broad-spectrum antibiotic being developed in oral tablet and intravenous formulations for use as a monotherapy antibiotic for bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP), urinary tract infections, and other serious community-acquired bacterial infections. The company has special protocol assessment agreements with The Food and Drug Administration (FDA) for the Phase III trials planned in ABSSSI and CABP. Its other product candidate, WC 3035 (sarecycline), is a new tetracycline-derived compound, with dual narrow-spectrum antibacterial and potent anti-inflammatory activity for the treatment of acne and rosacea in the community setting. The company has licensed rights of WC 3035 to Actavis, which has completed Phase II clinical trials for the treatment of acne and rosacea in the United States. Paratek Pharmaceuticals, Inc. is based in Boston, Massachusetts.

12 Employees
Last Reported Date: 10/2/14

paratek pharmaceuticals inc (PRTK) Top Compensated Officers

President, Chief Medical Officer and Director
Total Annual Compensation: $291.1K
Chief Compliance Officer, Vice President of A...
Total Annual Compensation: $265.9K
Vice President of Research and Development
Total Annual Compensation: $226.0K
Compensation as of Fiscal Year 2013.

paratek pharmaceuticals inc (PRTK) Key Developments

Paratek Pharmaceuticals, Inc. Presents at Jefferies 2015 Antibiotic Summit, Mar-18-2015

Paratek Pharmaceuticals, Inc. Presents at Jefferies 2015 Antibiotic Summit, Mar-18-2015 . Venue: New York City, New York, United States. Speakers: Evan Loh, President, Chief Medical Officer and Director.

Paratek Pharmaceuticals, Inc. Presents at BioCentury 22nd Annual Future Leaders in the Biotech Industry Conference, Mar-20-2015 02:00 PM

Paratek Pharmaceuticals, Inc. Presents at BioCentury 22nd Annual Future Leaders in the Biotech Industry Conference, Mar-20-2015 02:00 PM. Venue: Millennium Broadway Hotel & Conference Center, New York, New York, United States. Speakers: Michael F. Bigham, Chairman of the Board and Chief Executive Officer.

Paratek Pharmaceuticals, Inc. Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-02-2015 04:10 PM

Paratek Pharmaceuticals, Inc. Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-02-2015 04:10 PM. Venue: The Boston Marriott Copley Place, Boston, Massachusetts, United States. Speakers: Michael F. Bigham, Chairman of the Board and Chief Executive Officer.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PRTK:US $30.65 USD -0.88

PRTK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PRTK.
View Industry Companies
 

Industry Analysis

PRTK

Industry Average

Valuation PRTK Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 155.2x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 831.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PARATEK PHARMACEUTICALS INC, please visit www.paratekpharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.